Results 11 to 20 of about 591,781 (298)

Sunitinib for advanced renal cell cancer

Biologics: Targets & Therapy, 2008
Chris CoppinBC Cancer Agency and University of British Columbia, Vancouver, CanadaAbstract: Renal cell cancer has been refractory to drug therapy in the large majority of patients.
Chris Coppin
doaj   +1 more source

Quantitative proteomics in resected renal cancer tissue for biomarker discovery and profiling [PDF]

, 2014
BACKGROUND: Proteomics-based approaches for biomarker discovery are promising strategies used in cancer research. We present state-of-art label-free quantitative proteomics method to assess proteome of renal cell carcinoma (RCC) compared with noncancer ...
J T-J Huang, Bray, S E, Fleming, S., Lamont, D J, D J Lamont, Zakikhani, P, P Zakikhani, M A V Mudaliar, Atrih, A, S Fleming, Zakikhani, P., Lamont, D. J., Barton, G.; id_orcid, G Nabi, G Barton, A Atrih, Bray, S. E., Barton, G, Huang, J. T.-J.; id_orcid, Mudaliar, M. A. V., Atrih, A., Fleming, S, Nabi, G, Nabi, G., Huang, J T-J, S E Bray, Mudaliar, M A V   +26 more
core   +1 more source

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma

EBioMedicine, 2020
Background: Vorolanib (X-82, CM082) is a multi-target tyrosine kinase inhibitor. This study aimed to evaluate the tolerability, safety, pharmacokinetics and antitumor activities of vorolanib plus everolimus (an inhibitor of mammalian target of rapamycin).
Xinan Sheng, Xieqiao Yan, Zhihong Chi, Chuanliang Cui, Lu Si, Bixia Tang, Siming Li, Lili Mao, Bin Lian, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Lieming Ding, Li Mao, Jun Guo   +16 more
doaj   +1 more source

Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort

Journal for ImmunoTherapy of Cancer, 2021
Background Although the Society for Immunotherapy of Cancer (SITC) Immunotherapy Resistance Taskforce recently defined primary and secondary resistance to anti-programmed cell death protein 1 (anti-PD-1) therapy, there is lack of real-world data ...
Xiaoling Yang, Keith Flaherty, Jun Guo, Xue Bai, Michelle Kim, Gyulnara Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoting Wei, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Dennie Frederick, Genevieve Boland   +16 more
doaj   +1 more source

Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

Journal of Translational Medicine, 2019
Background Melanoma is one of the most aggressive cancers with extremely poor prognosis, and the median survival time for stage IV patients is approximately 6 to 8 months.
Longwen Xu, Zhiyuan Cheng, Chuanliang Cui, Xiaowen Wu, Huan Yu, Jun Guo, Yan Kong   +6 more
doaj   +1 more source

Correction to: Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy

Journal of Translational Medicine, 2019
Following publication of the original article [1], the authors reported errors in Figures 2, 3 and Figure 3 ‘continued’
Longwen Xu, Zhiyuan Cheng, Chuanliang Cui, Xiaowen Wu, Huan Yu, Jun Guo, Yan Kong   +6 more
doaj   +1 more source

Current strategies to diagnose and manage positive surgical margins and local recurrence after partial nephrectomy

Asian Journal of Urology, 2022
Objective: No standard strategy for diagnosis and management of positive surgical margin (PSM) and local recurrence after partial nephrectomy (PN) are reported in literature.
Umberto Carbonara, Daniele Amparore, Cosimo Gentile, Riccardo Bertolo, Selcuk Erdem, Alexandre Ingels, Michele Marchioni, Constantijn H.J. Muselaers, Onder Kara, Laura Marandino, Nicola Pavan, Eduard Roussel, Angela Pecoraro, Fabio Crocerossa, Giuseppe Torre, Riccardo Campi, Pasquale Ditonno   +16 more
doaj   +1 more source

Efficacy and Safety of Vemurafenib in Acral and Mucosal Melanoma Patients with BRAF Gene Mutation

Zhongliu Fangzhi Yanjiu, 2018
Objective To explore the efficacy and safety of Vemurafenib in acral and mucosal melanoma patients with BRAF gene mutation. Methods We retrospectively analyzed the clinical data of 24 patients diagnosed as BRAF gene-mutant acral melanoma (AM) or mucosal ...
WEI Xiaoting, BAI Xue, MAO Lili, CHI Zhihong, SHENG Xi'nan, CUI Chuanliang, WANG Xuan, LIAN Bin, TANG Bixia, YAN Xieqiao, LI Siming, ZHOU Li, GUO Jun, SI Lu   +13 more
doaj   +1 more source

Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse

Scientific Reports, 2021
Calcineurin inhibitors, such as Cyclosporin (CsA), are the mainstay of anti-rejection therapy in solid organ transplants but can paradoxically induce progressive nephropathy characterised by renal dysfunction and interstitial fibrosis.
Long T. Nguyen, Sonia Saad, Ying Shi, Rosy Wang, Angela S. Y. Chou, Anthony Gill, Yimin Yao, Wolfgang Jarolimek, Carol A. Pollock   +8 more
doaj   +1 more source

Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery [PDF]

, 2014
Background:Wider clinical applications of 9p status in clear cell renal cell carcinoma (ccRCC) are limited owing to the lack of validation and consensus for interphase fluorescent in situ hybridisation (I-FISH) scoring technique.
Fleming, S., P Rauchhaus, J Fitzpatrick, Fitzpatrick, J., N Pratt, S Fleming, J Bondad, J Cunningham, El-Mokadem, I., Cunningham, J., Bondad, J., Nabi, G., Rauchhaus, P., G Nabi, Pratt, N., I El-Mokadem   +15 more
core   +1 more source